| 書(shū)目名稱(chēng) | Liver Cirrhosis |
| 編輯 | Kiwamu Okita (Professor and Chairman) |
| 視頻video | http://file.papertrans.cn/588/587406/587406.mp4 |
| 概述 | Providing a valuable resource for physicians and hepatologists who are interested not only in fibrogenesis but also in hepatocarcinogenesis |
| 圖書(shū)封面 |  |
| 描述 | Since 1998, the Japanese Society of Hepatology has campaigned to fight hepatocellu- lar carcinoma (HCC). Because the mortality rate for this disease has reached more than 30 per 100,000 population, the organizing committee chose HCC as the main topic of the 1999 Yamaguchi Symposium on Liver Diseases. Regarding hepatocar- cinogenesis, we know that HCC often develops secondary to liver cirrhosis; thus liver cirrhosis must be recognized as a prevalent pathological condition leading to HCC. If we can control liver fibrosis, we can reduce the risk for HCC among patients with chronic hepatitis. To achieve this goal, we must know more about hepatic fibrosis. Professor Michael J. P. Arthur is familiar as a leading scientist in this field. We were fortunate that he accepted our invitation to speak. His lecture titled "Mechanisms of the Progression and Regression of Liver Fibrosis" provided important advice for developing antifibrotic agents. We also invited Professor Mark A. Zern, who has been studying hepatic fibrosis for some time. In the symposium he talked about novel approaches, including gene therapy, to treat acute and chronic hepatic diseases in the 21st century. In addition to the |
| 出版日期 | Conference proceedings 2001 |
| 關(guān)鍵詞 | Hepatic fibrosis; Hepatic stellate cell; Hepatocarcinogenesis; hepatitis; hepatology; liver; liver disease |
| 版次 | 1 |
| doi | https://doi.org/10.1007/978-4-431-68343-8 |
| isbn_softcover | 978-4-431-68345-2 |
| isbn_ebook | 978-4-431-68343-8 |
| copyright | Springer Japan 2001 |
|Archiver|手機(jī)版|小黑屋|
派博傳思國(guó)際
( 京公網(wǎng)安備110108008328)
GMT+8, 2025-10-14 04:42
發(fā)表于 2025-3-21 18:36:41
